Back to stock research
Earnings research
LLY Q1 2026
Lilly reported first-quarter 2026 results, raised full-year guidance and highlighted Mounjaro, Zepbound, orforglipron and broader pipeline progress.
Reported outcomes
- Revenue
- US$19.799 billion
- Up 56% year over year
- Reported diluted EPS
- US$8.26
- Up 170% year over year
- Revenue volume effect
- +65%
- Year-over-year contribution, partly offset by a 13% lower realized-price effect
Management guidance
- Lilly raised 2026 revenue guidance to US$82-US$85 billion and non-GAAP EPS guidance to US$35.50-US$37.00.
Market reaction
+13.17%
2026-04-29 $851.21 → 2026-05-01 $963.33
Prior trading close to first full trading-session close after the published release date
Open historical market dataPrimary sources
Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified
Fetched: 11.7.2026, 0:00:00 UTC
Open original sourceForm 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified
LLY editorial research profileAlphaVue Research · editorialVerified
Fetched: 11.7.2026, 0:00:00 UTC